Document:

Prepared by R.R. Donnelley Financial -- EX-10.3

 Exhibit 10.3 

CALITHERA BIOSCIENCES, INC. 

2010 EQUITY INCENTIVE PLAN 

OPTION AGREEMENT 

(INCENTIVE STOCK OPTION OR NONSTATUTORY STOCK
OPTION) 
 Pursuant to your Stock Option Grant Notice (“Grant Notice”) and this Option Agreement,
Calithera Biosciences, Inc. (the “Company”) has granted you an option under its 2010 Equity Incentive Plan (the “Plan”) to purchase the number of shares of the Company’s Common Stock indicated in
your Grant Notice at the exercise price indicated in your Grant Notice. Defined terms not explicitly defined in this Option Agreement but defined in the Plan shall have the same definitions as in the Plan. 

The details of your option are as follows: 

1. VESTING. Subject to the limitations contained herein, your option will vest as provided in your Grant Notice,
provided that vesting will cease upon the termination of your Continuous Service. 
 2. NUMBER OF
SHARES AND EXERCISE PRICE. The number of shares of Common Stock subject to your option and your exercise price per share referenced in your Grant Notice may be adjusted from time to
time for Capitalization Adjustments. 
 3. EXERCISE RESTRICTION FOR
NON-EXEMPT EMPLOYEES. In the event that you are an Employee eligible for overtime compensation under the Fair Labor Standards Act of 1938, as amended (i.e., a “Non-Exempt
Employee”), you may not exercise your option until you have completed at least six (6) months of Continuous Service measured from the Date of Grant specified in your Grant Notice, notwithstanding any other provision of your option.

 4. EXERCISE PRIOR TO VESTING (“EARLY
EXERCISE”). If permitted in your Grant Notice (i.e., the “Exercise Schedule” indicates “Early Exercise Permitted”) and subject to the provisions of your option, you may elect at any time that is
both (i) during the period of your Continuous Service and (ii) during the term of your option, to exercise all or part of your option, including the unvested portion of your option; provided, however, that: 

(a) a partial exercise of your option shall be deemed to cover first vested shares of Common Stock and then the earliest vesting
installment of unvested shares of Common Stock; 
 (b) any shares of Common Stock so purchased from installments that have not vested
as of the date of exercise shall be subject to the purchase option in favor of the Company as described in the Company’s form of Early Exercise Stock Purchase Agreement; 

(c) you shall enter into the Company’s form of Early Exercise Stock Purchase Agreement with a vesting schedule that will result in
the same vesting as if no early exercise had occurred; and 

  
 1. 

 (d) if your option is an Incentive Stock Option, then, to the extent that the aggregate
Fair Market Value (determined at the time of grant) of the shares of Common Stock with respect to which your option plus all other Incentive Stock Options you hold are exercisable for the first time by you during any calendar year (under all plans
of the Company and its Affiliates) exceeds one hundred thousand dollars ($100,000), your option(s) or portions thereof that exceed such limit (according to the order in which they were granted) shall be treated as Nonstatutory Stock Options. 

5. METHOD OF PAYMENT. Payment of the exercise price is due in full upon exercise of all or
any part of your option. You may elect to make payment of the exercise price in cash or by check or in any other manner permitted by your Grant Notice, which may include one or more of the following: 

(a) Provided that at the time of exercise the Common Stock is publicly traded and quoted regularly in The Wall Street Journal,
pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of Common Stock, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to
pay the aggregate exercise price to the Company from the sales proceeds. 
 (b) Provided that at the time of exercise the Common
Stock is publicly traded and quoted regularly in The Wall Street Journal, by delivery to the Company (either by actual delivery or attestation) of already-owned shares of Common Stock that are owned free and clear of any liens, claims,
encumbrances or security interests, and that are valued at Fair Market Value on the date of exercise. Notwithstanding the foregoing, you may not exercise your option by tender to the Company of Common Stock to the extent such tender would violate
the provisions of any law, regulation or agreement restricting the redemption of the Company’s stock. 
 (c) Pursuant to the
following deferred payment alternative: 
 (i) Not less than one hundred percent (100%) of the aggregate exercise price, plus
accrued interest, shall be due four (4) years from date of exercise or, at the Company’s election, upon termination of your Continuous Service. 

(ii) Interest shall be compounded at least annually and shall be charged at the minimum rate of interest necessary to avoid
(1) the treatment as interest, under any applicable provisions of the Code, of any amounts other than amounts stated to be interest under the deferred payment arrangement and (2) the classification of your option as a liability for
financial accounting purposes. 
 (iii) In order to elect the deferred payment alternative, you must, as a part of your written
notice of exercise, give notice of the election of this payment alternative and, in order to secure the payment of the deferred exercise price to the Company hereunder, if the Company so requests, you must tender to the Company a promissory note and
a pledge agreement covering the purchased shares of Common Stock, both in form and substance satisfactory to the Company, or such other or additional documentation as the Company may request. 

  
 2. 

 6. WHOLE SHARES. You may exercise your option only for whole
shares of Common Stock. 
 7. SECURITIES LAW COMPLIANCE. Notwithstanding anything to the
contrary contained herein, you may not exercise your option unless the shares of Common Stock issuable upon such exercise are then registered under the Securities Act or, if such shares of Common Stock are not then so registered, the Company has
determined that such exercise and issuance would be exempt from the registration requirements of the Securities Act. The exercise of your option also must comply with other applicable laws and regulations governing your option, and you may not
exercise your option if the Company determines that such exercise would not be in material compliance with such laws and regulations. 

8. TERM. You may not exercise your option before the commencement or after the expiration of its term. The term of your
option commences on the Date of Grant and expires upon the earliest of the following: 
 (a) three (3) months after the
termination of your Continuous Service for any reason other than your Disability or death, provided that if during any part of such three (3) month period your option is not exercisable solely because of the condition set forth in the section
above relating to “Securities Law Compliance,” your option shall not expire until the earlier of the Expiration Date or until it shall have been exercisable for an aggregate period of three (3) months after the termination of your
Continuous Service; 
 (b) twelve (12) months after the termination of your Continuous Service due to your Disability; 

(c) eighteen (18) months after your death if you die either during your Continuous Service or within three (3) months after
your Continuous Service terminates; 
 (d) the Expiration Date indicated in your Grant Notice; or 

(e) the day before the tenth (10th) anniversary of the Date of Grant. 

If your option is an Incentive Stock Option, note that to obtain the federal income tax advantages associated with an Incentive Stock Option,
the Code requires that at all times beginning on the date of grant of your option and ending on the day three (3) months before the date of your option’s exercise, you must be an employee of the Company or an Affiliate, except in the event
of your death or Disability. The Company has provided for extended exercisability of your option under certain circumstances for your benefit but cannot guarantee that your option will necessarily be treated as an Incentive Stock Option if you
continue to provide services to the Company or an Affiliate as a Consultant or Director after your employment terminates or if you otherwise exercise your option more than three (3) months after the date your employment with the Company or an
Affiliate terminates. 

  
 3. 

 9. EXERCISE. 

(a) You may exercise the vested portion of your option (and the unvested portion of your option if your Grant Notice so permits) during
its term by delivering a Notice of Exercise (in a form designated by the Company) together with the exercise price to the Secretary of the Company, or to such other person as the Company may designate, during regular business hours, together with
such additional documents as the Company may then require. 
 (b) By exercising your option you agree that, as a condition to any
exercise of your option, the Company may require you to enter into an arrangement providing for the payment by you to the Company of any tax withholding obligation of the Company arising by reason of (1) the exercise of your option,
(2) the lapse of any substantial risk of forfeiture to which the shares of Common Stock are subject at the time of exercise, or (3) the disposition of shares of Common Stock acquired upon such exercise. 

(c) If your option is an Incentive Stock Option, by exercising your option you agree that you will notify the Company in writing within
fifteen (15) days after the date of any disposition of any of the shares of the Common Stock issued upon exercise of your option that occurs within two (2) years after the date of your option grant or within one (1) year after such
shares of Common Stock are transferred upon exercise of your option. 
 (d) By exercising your option you agree that you shall not
sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale, any shares of Common Stock or other securities of the Company held by
you, for a period of one hundred eighty (180) days following the effective date of a registration statement of the Company filed under the Securities Act or such longer period as necessary to permit compliance with NASD Rule 2711 or NYSE Member
Rule 472 and similar rules and regulations (the “Lock-Up Period”); provided, however, that nothing contained in this section shall prevent the exercise of a repurchase option, if any, in favor of the Company during the
Lock-Up Period. You further agree to execute and deliver such other agreements as may be reasonably requested by the Company and/or the underwriter(s) that are consistent with the foregoing or that are necessary to give further effect thereto. In
order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to your shares of Common Stock until the end of such period. The underwriters of the Company’s stock are intended third party beneficiaries
of this Section 9(d) and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. 

10. TRANSFERABILITY. Your option is not transferable, except by will or by the laws of descent and distribution, and is
exercisable during your life only by you. Notwithstanding the foregoing, by delivering written notice to the Company, in a form satisfactory to the Company, you may designate a third party who, in the event of your death, shall thereafter be
entitled to exercise your option. In addition, if permitted by the Company you may transfer your option to a trust if you are considered to be the sole beneficial owner (determined under Section 671 of the Code and applicable state law) while
the option is held in the trust, provided that you and the trustee enter into a transfer and other agreements required by the Company. 

11. RIGHT OF FIRST REFUSAL. Shares of Common Stock that you acquire upon
exercise of your option are subject to any right of first refusal that may be described in the Company’s bylaws in effect at such time the Company elects to exercise its right; provided, however, that if your option is an Incentive Stock
Option and the right of first refusal described in the Company’s bylaws in effect at the time the Company elects to exercise its right is more 

  
 4. 

 
beneficial to you than the right of first refusal described in the Company’s bylaws on the Date of Grant, then the right of first refusal described in the Company’s bylaws on the Date
of Grant shall apply. The Company’s right of first refusal shall expire on the first date upon which any security of the Company is listed (or approved for listing) upon notice of issuance on a national securities exchange or quotation system.

 12. RIGHT OF REPURCHASE. To the extent provided in the Company’s bylaws in
effect at such time the Company elects to exercise its right, the Company shall have the right to repurchase all or any part of the shares of Common Stock you acquire pursuant to the exercise of your option. 

13. OPTION NOT A SERVICE CONTRACT. Your option is not an
employment or service contract, and nothing in your option shall be deemed to create in any way whatsoever any obligation on your part to continue in the employ of the Company or an Affiliate, or of the Company or an Affiliate to continue your
employment. In addition, nothing in your option shall obligate the Company or an Affiliate, their respective stockholders, Boards of Directors, Officers or Employees to continue any relationship that you might have as a Director or Consultant for
the Company or an Affiliate. 
 14. WITHHOLDING OBLIGATIONS. 

(a) At the time you exercise your option, in whole or in part, or at any time thereafter as requested by the Company, you hereby
authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for (including by means of a “cashless exercise” pursuant to a program developed under Regulation T as promulgated by
the Federal Reserve Board to the extent permitted by the Company), any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or an Affiliate, if any, which arise in connection with the exercise of
your option. 
 (b) Upon your request and subject to approval by the Company, in its sole discretion, and compliance with any
applicable legal conditions or restrictions, the Company may withhold from fully vested shares of Common Stock otherwise issuable to you upon the exercise of your option a number of whole shares of Common Stock having a Fair Market Value, determined
by the Company as of the date of exercise, not in excess of the minimum amount of tax required to be withheld by law (or such lower amount as may be necessary to avoid classification of your option as a liability for financial accounting purposes).
If the date of determination of any tax withholding obligation is deferred to a date later than the date of exercise of your option, share withholding pursuant to the preceding sentence shall not be permitted unless you make a proper and timely
election under Section 83(b) of the Code, covering the aggregate number of shares of Common Stock acquired upon such exercise with respect to which such determination is otherwise deferred, to accelerate the determination of such tax
withholding obligation to the date of exercise of your option. Notwithstanding the filing of such election, shares of Common Stock shall be withheld solely from fully vested shares of Common Stock determined as of the date of exercise of your option
that are otherwise issuable to you upon such exercise. Any adverse consequences to you arising in connection with such share withholding procedure shall be your sole responsibility. 

  
 5. 

 (c) You may not exercise your option unless the tax withholding obligations of the Company
and/or any Affiliate are satisfied. Accordingly, you may not be able to exercise your option when desired even though your option is vested, and the Company shall have no obligation to issue a certificate for such shares of Common Stock or release
such shares of Common Stock from any escrow provided for herein unless such obligations are satisfied. 
 15. TAX
CONSEQUENCES. You hereby agree that the Company does not have a duty to design or administer the Plan or its other compensation programs in a manner that minimizes your tax liabilities. You shall not make any claim
against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from your option or your other compensation. In particular, you acknowledge that this option is exempt from Section 409A of the
Code only if the exercise price per share specified in the Grant Notice is at least equal to the “fair market value” per share of the Common Stock on the Date of Grant and there is no other impermissible deferral of compensation associated
with the option. Because the Common Stock is not traded on an established securities market, the Fair Market Value is determined by the Board, perhaps in consultation with an independent valuation firm retained by the Company. You acknowledge that
there is no guarantee that the Internal Revenue Service will agree with the valuation as determined by the Board, and you shall not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates in the event that the
Internal Revenue Service asserts that the valuation determined by the Board is less than the “fair market value” as subsequently determined by the Internal Revenue Service. 

16. NOTICES. Any notices provided for in your option or the Plan shall be given in writing and shall be deemed
effectively given upon receipt or, in the case of notices delivered by mail by the Company to you, five (5) days after deposit in the United States mail, postage prepaid, addressed to you at the last address you provided to the Company. 

17. GOVERNING PLAN DOCUMENT. Your option is subject to all the provisions of the Plan, the
provisions of which are hereby made a part of your option, and is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan. In the event of any conflict
between the provisions of your option and those of the Plan, the provisions of the Plan shall control. 

  
 6. 

 CALITHERA BIOSCIENCES, INC. 

2010 EQUITY INCENTIVE PLAN 

STOCK OPTION GRANT NOTICE 

Calithera Biosciences, Inc. (the “Company”), pursuant to its 2010 Equity Incentive Plan (as amended and/or restated to date, the
“Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth herein and in the
Option Agreement, the Plan, and the Notice of Exercise, all of which are attached hereto and incorporated herein in their entirety. 
  

					
	Optionholder:	 	  
	  	
	Date of Grant:	 	  
	  	
	Vesting Commencement Date:	 	  
	  	
	Number of Shares Subject to Option:	 	  
	  	
	Exercise Price (Per Share):	 	  
	  	
	Total Exercise Price:	 	  
	  	
	Expiration Date:	 	  
	  	

							
				
	Type of Grant:	 	 ̈  Incentive Stock Option1	 	             ̈  Nonstatutory Stock Option	 	

 [DRAFTING NOTE: Options that are exercisable by non-exempt employees (those subject to wage overtime rules) within six
months after the date of grant may affect the calculations of overtime wages. Therefore, options granted to non-exempt employees should not be exercisable for at least six months from the grant date; provided, that the employees may exercise if
their employment is terminated due to a change in control, their death or retirement.] 
  

							
	Exercise Schedule:	 	 ̈  Same as Vesting Schedule	 	       ̈  Early Exercise Permitted
		
	Vesting Schedule:	 	[SAMPLE: 1/4th of the shares vest one year after the Vesting Commencement Date; the balance of
the shares vest in a series of
thirty-six (36) successive equal monthly installments measured from
the first anniversary of the Vesting Commencement Date.]
		
	Payment:	 	By one or a combination of the following items (described in the Option Agreement):
		
	 	 	x  By cash or check
	 	 	x  Pursuant to a Regulation T Program if the Shares are publicly traded
	 	 	x  By delivery of already-owned shares if the Shares are publicly traded
	 	 	 ̈  By deferred payment
	 	 	 ̈  By net exercise2

 Additional Terms/Acknowledgements: The undersigned Optionholder acknowledges receipt of, and understands and agrees to,
this Stock Option Grant Notice, the Option Agreement and the Plan. Optionholder further acknowledges that as of the Date of Grant, this Stock Option Grant Notice, the Option Agreement, and the Plan set forth the entire understanding between
Optionholder and the Company regarding the acquisition of stock in the Company and supersede all prior oral and written agreements on that subject with the exception of (i) options previously granted and delivered to Optionholder under the
Plan, and (ii) the following agreements only: 
  

					
	OTHER AGREEMENTS:	 		 	  

		 		 	  

  

	1 	If this is an Incentive Stock Option, it (plus other outstanding Incentive Stock Options) cannot be first exercisable for more than $100,000 in value (measured by exercise price) in any calendar year. Any excess
over $100,000 is a Nonstatutory Stock Option. 

	2 	An Incentive Stock Option may not be exercised by a net exercise arrangement. 

									
	PROTEIN ACTIVATION THERAPEUTICS, INC.	 		 	OPTIONHOLDER:
				
	By:	 	  
	 		 	  

		 	Signature	 		 	Signature
					
	Title:	 	  
	 		 	Date:	 	  

					
	Date:	 	  
	 		 		 	

 ATTACHMENTS: Option Agreement, 2010 Equity Incentive Plan and Notice of Exercise 

 ATTACHMENT I 

OPTION AGREEMENT 

 ATTACHMENT II 

2010 EQUITY INCENTIVE PLAN 

 ATTACHMENT III 

NOTICE OF EXERCISEPrepared by R.R. Donnelley Financial -- EX-10.7

 Exhibit 10.7 

CALITHERA BIOSCIENCES INC. 
 SUSAN
MOLINEAUX EMPLOYMENT AGREEMENT 
 This Agreement is entered into as of June 1, 2010 (the “Effective Date”) by and between
Calithera Biosciences Inc. (the “Company”) and Susan Molineaux (“Executive”). 
 1. Duties and Scope of
Employment. 
 (a) Positions and Duties. As of the Effective Date, Executive serves and will serve as the President and Chief
Executive Officer of the Company. Executive will render such business and professional services in the performance of Executive’s duties, consistent with Executive’s position within the Company, as will be assigned to her by the
Company’s Board of Directors (the “Board”). The period of Executive’s employment under this Agreement is referred to herein as the “Employment Term. 

(b) Obligations. During the Employment Term, Executive will perform Executive’s duties faithfully and to the best of
Executive’s ability and will devote Executive’s full business efforts and time to the Company. For the duration of the Employment Term, Executive agrees not to actively engage in any other employment, occupation or consulting activity for
any direct or indirect remuneration without the prior approval of the Board. 
 2. At-Will Employment. The parties agree that
Executive’s employment with the Company will be “at-will” employment and may be terminated at any time with or without cause or advance notice. Executive understands and agrees that neither Executive’s job performance nor
promotions, commendations, bonuses or the like from the Company shall give rise to or in any way serve as the basis for modification, amendment, or extension, by implication or otherwise, of Executive’s employment with the Company. However, as
described in this Agreement, Executive may be entitled to severance benefits depending on the circumstances of Executive’s termination of employment with the Company. 

3. Compensation. 
 (a)
Base Salary. During the Employment Term, the Company will pay Executive an annual salary of $350,000 as compensation for Executive’s services (the “Base Salary”). The Base Salary will be paid periodically in accordance with the
Company’s normal payroll practices and be subject to the usual, required withholdings and deductions. Executive’s salary will be subject to review and adjustments based upon the Company’s normal performance review practices, to be
established. 
 (b) Bonus. Executive will also be eligible to participate in such annual cash bonus plans as the Company, in its sole
and absolute discretion, may establish from time to time. Under such annual cash bonus plans or an individual cash bonus plan or all such plans, Executive shall be entitled to be eligible for a management incentive bonus (“Management
Bonus”), up to a target bonus amount of thirty-five percent (35%) of Executive’s Base Salary, and contingent upon the achievement of such corporate milestones as may be established by the Company. Executive understands and agrees that
the determinations of milestone criteria (both the criteria and Executive’s performance of such criteria) and the amount, if any, of Executive’s Management Bonus shall be within the sole and absolute discretion of the Company. The Company
shall determine and provide notice to Executive of such milestone criteria and target bonus amounts not later than four (4) months after the start of the calendar year to which such criteria and bonus or bonuses shall relate. Any Management
Bonus awarded shall be paid prior to March 15 of the following year. Except as provided in Section 7 below, no Management Bonus will be earned or payable in the event Executive’s employment terminates, for any reason, before the end
of the applicable calendar year. 

 (c) Restricted Stock Purchase Agreement. Executive acknowledges that Executive has entered
into a Restricted Stock Purchase Agreement dated March 24, 2010 between Executive and the Company, as amended as of the Effective Date (the “RSPA”), pursuant to which Executive purchased 5,280,000 shares of the Company’s Common
Stock, 4,400,000 shares of which (the “RSPA Shares”) are subject to a right of repurchase by the Company which lapses as set forth in the RSPA, the terms of which are recited here for convenience and in no way as a modification of the
express language of the RSPA: the Company’s right of repurchase will lapse as to one forty-eighth (1/48th) of the RSPA Shares on each one month anniversary following the initial closing
of the Company’s Series A Preferred Stock financing dated as of the date hereof (the “Initial Closing”) subject to Executive’s continued employment by the Company as its Chief Executive Officer, until all RSPA Shares are
released from the Company’s right of repurchase on the four year anniversary of the date of the Initial Closing. 
 4. Employee
Benefits. During the Employment Term, Executive will be entitled to participate in the employee benefit plans currently and hereafter maintained by the Company of general applicability to other senior executives of the Company, subject to the
terms and conditions of such plans. The Company reserves the right to cancel or change the benefit plans and programs it offers to its employees at any time. 

5. Vacation. Executive will be entitled to paid vacation in accordance with the Company’s vacation policy, with the timing and
duration of specific vacations mutually and reasonably agreed to by the parties hereto. Upon Executive’s termination of employment, Executive will be entitled to receive Executive’s accrued but unpaid vacation through the date of
Executive’s termination. 
 6. Expenses. The Company will reimburse Executive for reasonable travel, entertainment or other
expenses incurred by Executive in the furtherance of or in connection with the performance of Executive’s duties hereunder, in accordance with the Company’s expense reimbursement policy to be established and as in effect from time to time.

 7. Severance Benefits. 

(a) Termination without Cause; Resignation with Good Reason. If Executive’s employment with the Company is terminated by the
Company (or by its successor following a Change of Control) without Cause and other than as a result of her death or disability, or if Executive resigns from her employment with the Company (or with its successor following a Change of Control) with
Good Reason, and in either case provided such termination constitutes a “separation from service” (as defined under Treasury Regulation Section 1.409A-1(h)), then, subject to Sections 7(b), 7(c) and 7(f) below, Executive will receive
the following severance from the Company: 
 (i) Severance Payment. Executive will receive severance pay in an amount equal, in the
aggregate, to the sum of (x) one year of Executive’s Base Salary (as in effect immediately prior to Executive’s termination) plus (y) a prorated portion of Executive’s target Management Bonus for the year in which
Executive’s employment is terminated, calculated based on the Company’s proportional accomplishment of that year’s goals through the date of Executive’s termination (the “Prorated Bonus”) less applicable withholdings,
to be paid as set forth in Section 7(c) below. In the event Executive’s termination occurs following a Change of Control (as defined herein), then in lieu of the Prorated Bonus, Executive shall receive 100% of Executive’s target
Management Bonus for the year in which Executive’s employment is terminated; 
 (ii) Accelerated Vesting. If Executive holds
unvested equity awards, then one hundred percent (100%) of the unvested portion of each equity award (including the RSPA) will immediately vest and become exercisable, and all equity awards held by Executive will remain exercisable, to the
extent vested and applicable, following the termination for the period prescribed in the respective stock plan and 

  
 2 

 
agreement for each equity award; provided, however, that Executive shall be permitted to exercise each of Executive’s equity awards for a period of 120 days from the date of
Executive’s termination (but in no event after the last day of the original term for such option and in no way shall this provision be read as an obligation upon the Company to ensure that any acquirer or successor in a Change of Control or
other similar transaction assume Executive’s options so as to allow for such full 120 day period). 
 (iii) Continued Employee
Benefits. If Executive timely elects continued coverage under COBRA, then the Company shall pay the COBRA premiums necessary to continue Executive’s medical insurance coverage in effect for Executive and Executive’s eligible dependents
on the termination date for the first twelve (12) months of such coverage (provided that such COBRA reimbursement shall terminate on such earlier date as Executive or her dependents are no longer eligible for COBRA coverage). 

(b) Separation Agreement and Release of Claims. The receipt of any severance pay or other benefits pursuant to Section 7(a) above
will be subject to, and conditioned upon, Executive (i) resigning from the Board; and (ii) signing and not revoking a separation agreement and release of claims with the Company in a form acceptable to the Company and substantially in the
form of Exhibit A hereto and that is effective no later than 60 days following the termination of her employment. 
 (c) Timing of
Severance Payments. The Company will pay the severance amount payable to Executive under Section 7(a)(i) over the twelve (12) month period immediately following Executive’s termination, in substantially equal installments, on the
Company’s regular payroll schedule; provided, however, that no severance amounts or benefits will be paid or provided until the separation agreement and release of claims described in Section 7(b) becomes effective or prior to the 60th day after Executive’s termination. Any severance amounts or benefits that would otherwise become payable (but for the delay in the foregoing sentence) between the date of Executive’s
termination and the 60th day shall be paid on the 60th day, with the balance of the severance paid on the original schedule set forth above. 

(d) Termination for Cause; Death or Disability; Resignation without Good Reason. If Executive’s employment with the Company (or
any parent or subsidiary of the Company) terminates due to Executive’s resignation (except upon resignation for Good Reason), for Cause by the Company or due to Executive’s death or disability, then (i) all vesting will terminate
immediately with respect to Executive’s outstanding equity awards, (ii) all payments of compensation by the Company to Executive hereunder will terminate immediately (except as to amounts already earned through the date of termination),
and (iii) Executive will only be eligible for severance benefits in accordance with the Company’s established policies, if any, as then in effect. 

(e) Section 409A. 

(i) Notwithstanding anything to the contrary in this Agreement, if Executive is a “specified employee” within the meaning of
Section 409A of the Code and the final regulations and any guidance promulgated thereunder (“Section 409A”) at the time of Executive’s termination (other than due to death), then to the extent that the payments upon a termination
of employment are determined to be “nonqualified deferred compensation” under Section 409A, such severance amounts, together with any other severance payments or separation benefits that are considered deferred compensation under
Section 409A (together, the “Deferred Compensation Separation Benefits”) that would otherwise be payable within the first six (6) months following Executive’s termination of employment, will instead become payable in a lump
sum on the first payroll date that occurs on or after the date six (6) months and one (1) day following (x) the date of Executive’s termination of employment or (y) the date of Executive’s death, if earlier. All
subsequent Deferred Compensation Separation Benefits, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit. Each payment and benefit payable under this Agreement is intended to constitute separate
payments for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations. 

  
 3 

 (ii) Any amount paid under the Agreement that satisfies the requirements of the “short-term
deferral” rule set forth in Section 1.409A-1(b)(4) of the Treasury Regulations shall not constitute Deferred Compensation Separation Benefits for purposes of clause (i) above. 

(iii) Any amount paid under this Agreement that qualifies as a payment made as a result of an involuntary separation from service pursuant to
Section 1.409A-1(b)(9)(iii) of the Treasury Regulations that does not exceed the Section 409A Limit (as defined below) will not constitute Deferred Compensation Separation Benefits for purposes of clause (i) above. 

(iv) The foregoing provisions are intended to comply with the requirements of Section 409A so that none of the severance payments and
benefits to be provided hereunder will be subject to the additional tax imposed under Section 409A, and any ambiguities herein will be interpreted to so comply. Executive and the Company agree to work together in good faith to consider
amendments to this Agreement and to take such reasonable actions which are necessary, appropriate or desirable to avoid imposition of any additional tax or income recognition prior to actual payment to Executive under Section 409A. However, the
Company is under no obligation to reimburse or otherwise make Executive whole for any amounts that may be subject to the additional tax or early income recognition under Section 409A. 

8. Limitation on Payments. In the event that the severance and other benefits provided for in this Agreement or otherwise payable to
Executive (i) constitute “parachute payments” within the meaning of Section 280G of the Code and (ii) but for this Section 8, would be subject to the excise tax imposed by Section 4999 of the Code, then
Executive’s severance benefits will be either: 
 (a) delivered in full, or 

(b) delivered as to such lesser extent which would result in no portion of such severance benefits being subject to the excise tax under
Section 4999 of the Code, whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999, results in the receipt by Executive on an after-tax basis,
of the greatest amount of severance benefits, notwithstanding that all or some portion of such severance benefits may be taxable under Section 4999 of the Code. If a reduction in the severance and other benefits constituting “parachute
payments” is necessary so that no portion of such severance benefits is subject to the excise tax under Section 4999 of the Code, the reduction shall occur in the following order: (1) reduction of cash payments; (2) cancellation
of accelerated vesting of equity awards other than stock options; (3) cancellation of accelerated vesting of stock options; and (4) reduction of other benefits paid to you. . In the event that acceleration of vesting of Award compensation
is to be reduced, such acceleration of vesting shall be cancelled in the reverse order of the date of grant of Executive’s Awards. In no event will the Company or any stockholder be liable to you for any amounts not paid as a result of the
operation of this Section 8. 
 Unless the Company and Executive otherwise agree in writing, any determination required under this
Section 8 will be made in writing by an independent firm immediately prior to Change of Control (the “Firm”), whose determination will be conclusive and binding upon Executive and the Company for all purposes. For purposes of making
the calculations required by this Section 8, the Firm may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of
the Code. The Company and Executive will furnish to the Firm such information and documents as the Firm may reasonably request in order to make a determination under this Section. The Company will bear all costs the Firm may reasonably incur in
connection with any calculations contemplated by this Section 8. Any good faith determinations of the tax firm made hereunder will be final, binding and conclusive upon the Company and Executive. 

  
 4 

 9. Definitions. 

(a) Cause. For purposes of this Agreement, “Cause” is defined as (i) Executive’s conviction of or plea of nolo
contendere to any felony or any crime involving moral turpitude or dishonesty; (ii) Executive’s gross misconduct in the performance of Executive’s duties which is injurious to the Company; (iii) failure by Executive to
substantially perform Executive’s material duties other than a failure resulting from the Executive’s complete or partial incapacity due to physical or mental illness or impairment; (iv) a material breach of any material agreement
between Executive and the Company concerning the terms and conditions of Executive’s employment with the Company; (v) Executive’s willful violation of a material Company employment policy (including, without limitation, any insider
trading policy); or (vi) Executive’s willful commission of an act of fraud, breach of trust, or dishonesty including, without limitation, embezzlement, that results in material damage or harm to the business, financial condition,
reputation or assets of the Company or any of its subsidiaries. Grounds for Cause pursuant to clause (iii) of this Section 9(b) shall not be deemed to have occurred until Company has first provided Executive with written notice of the acts
or omissions constituting the grounds for “Cause” under clause (iii) of this Section 9(b) and a cure period of thirty (30) days following the date of such notice. 

(b) Change of Control. For purposes of this Agreement, “Change of Control” means the occurrence of any of the following
events: 
 (i) Change in Ownership of the Company. A change in the ownership of the Company which occurs on the date that any one
person, or more than one person acting as a group (“Person”), acquires ownership of the stock of the Company that, together with the stock held by such Person, constitutes more than 50% of the total voting power of the stock of the
Company, except that any change in the ownership of the stock of the Company as a result of a private financing of the Company that is approved by the Board will not be considered a Change of Control; or 

(ii) Change in Ownership of a Substantial Portion of the Company’s Assets. A change in the ownership of a substantial portion of
the Company’s assets which occurs on the date that any Person acquires (or has acquired during the twelve (12) month period ending on the date of the most recent acquisition by such person or persons) assets from the Company that have a
total gross fair market value equal to or more than 50% of the total gross fair market value of all of the assets of the Company immediately prior to such acquisition or acquisitions. For purposes of this clause (3), gross fair market value means
the value of the assets of the Company, or the value of the assets being disposed of, determined without regard to any liabilities associated with such assets. 

For these purposes, persons will be considered to be acting as a group if they are owners of a corporation that enters into a merger,
consolidation, purchase or acquisition of stock, or similar business transaction with the Company. 
 Notwithstanding the foregoing, a
transaction shall not constitute a Change of Control if: (i) its sole purpose is to change the state of the Company’s incorporation; (ii) its sole purpose is to create a holding company that will be owned in substantially the same
proportions by the persons who held the Company’s securities immediately before such transaction; or (iii) it does not constitute a change of control event under Treasury Regulation 1.409A-3(i)(5)(v) or (vii). 

  
 5 

 (c) Good Reason. For purposes of this Agreement, “Good Reason” means
Executive’s resignation within thirty (30) days following the expiration of any Company cure period (discussed below) following the occurrence of one or more of the following, without Executive’s consent: (i) the assignment to
Executive of any duties, or the reduction of Executive’s duties, either of which results in a material diminution of Executive’s authority, duties, or responsibilities with the Company in effect immediately prior to such assignment or
reduction, or the removal of Executive from such position and responsibilities; (ii) a material reduction of Executive’s Base Salary except in connection with a general reduction in salary applicable to all of the Company’s executive
officers other than in connection with or following a Change in Control; (iii) the relocation of the Company’s facility to a location that results in an increase in Executive’s one-way commute by more than thirty (30) miles; and
(iv) any material breach by the Company of any material provision of this Agreement. Executive will not resign for Good Reason without first providing the Company with written notice of the acts or omissions constituting the grounds for
“Good Reason” within ninety (90) days of the initial existence of the grounds for “Good Reason” and a cure period of thirty (30) days following the date of such notice. 

(d) Section 409A Limit. For purposes of this Agreement, “Section 409A Limit” means the lesser of two (2) times:
(i) Executive’s annualized compensation based upon the annual rate of pay paid to Executive during the Company’s taxable year preceding the Company’s taxable year of Executive’s termination of employment as determined under
Treasury Regulation 1.409A-1(b)(9)(iii)(A)(1) and any Internal Revenue Service guidance issued with respect thereto; or (ii) the maximum amount that may be taken into account under a qualified plan pursuant to Section 401(a)(17) of the
Code for the year in which Executive’s employment is terminated. 
 10. Successors. 

(a) The Company’s Successors. Any successor to the Company (whether direct or indirect and whether by purchase, merger,
consolidation, liquidation or otherwise) to all or substantially all of the Company’s business and/or assets will assume the obligations under this Agreement and agree expressly to perform the obligations under this Agreement in the same manner
and to the same extent as the Company would be required to perform such obligations in the absence of a succession. For all purposes under this Agreement, the term “Company” will include any successor to the Company’s business and/or
assets which executes and delivers the assumption agreement described in this Section 10(a) or which becomes bound by the terms of this Agreement by operation of law. The failure of the Company to obtain the assumption of this Agreement by any
successor will constitute a material breach of a material part of this Agreement. 
 (b) Executive’s Successors. The terms of
this Agreement and all rights of Executive hereunder will inure to the benefit of, and be enforceable by, Executive’s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. 

11. Confidential Information. Executive agrees to enter into the Company’s standard Confidential Information and Invention
Assignment Agreement (the “Confidential Information Agreement”) upon commencing employment hereunder. 

  
 6 

 12. Notices. All notices, requests, demands and other communications called for hereunder
will be in writing and will be deemed given (i) on the date of delivery if delivered personally, (ii) one (1) day after being sent by a well established commercial overnight service, or (iii) four (4) days after being mailed
by registered or certified mail, return receipt requested, prepaid and addressed to the parties or their successors at the following addresses, or at such other addresses as the parties may later designate in writing: 

If to the Company: 

Calithera Biosciences, Inc. 

343 Oyster Point Boulevard, Suite 200 

South San Francisco, California 94080 

Attn: Corporate Secretary 

If to Executive: 

at the last residential address known by the Company. 

13. Arbitration. 
 (a)
Arbitration. In consideration of Executive’s employment with the Company, its promise to arbitrate all employment-related disputes, and Executive’s receipt of the compensation, pay raises and other benefits paid to Executive by the
Company, at present and in the future, Executive agrees that any and all controversies, claims, or disputes with anyone (including the Company and any employee, officer, director, shareholder or benefit plan of the Company in their capacity as such
or otherwise) arising out of, relating to, or resulting from Executive’s employment with the Company or termination thereof, including any breach of this Agreement, will be subject to binding arbitration under the Arbitration Rules set forth in
California Code of Civil Procedure Section 1280 through 1294.2, including Section 1281.8 (the “Act”), and pursuant to California law. The Federal Arbitration Act shall also continue to apply with full force and effect,
notwithstanding the application of procedural rules set forth under the Act. 
 (b) Dispute Resolution. Disputes that Executive
agrees to arbitrate, and thereby agrees to waive any right to a trial by jury, include any statutory claims under local, state, or federal law, including, but not limited to, claims under Title VII of the Civil Rights Act of 1964, the Americans with
Disabilities Act of 1990, the Age Discrimination in Employment Act of 1967, the Older Workers Benefit Protection Act, the Sarbanes Oxley Act, the Worker Adjustment and Retraining Notification Act, the California Fair Employment and Housing Act, the
Family and Medical Leave Act, the California Family Rights Act, the California Labor Code, Claims of harassment, discrimination, and wrongful termination, and any statutory or common law claims. Executive further understands that this Agreement to
arbitrate also applies to any disputes that the Company may have with Executive. The Arbitrator shall be required to provide a written opinion stating the legal and factual bases for his or her decision. 

(c) Procedure. Executive agrees that any arbitration will be administered by the Judicial Arbitration & Mediation Services,
Inc. (“JAMS”), pursuant to its Employment Arbitration Rules & Procedures (the “JAMS Rules”). The arbitrator shall have the power to decide any motions brought by any party to the arbitration, including motions for
summary judgment and/or adjudication, motions to dismiss and demurrers, and motions for class certification, prior to any arbitration hearing. The arbitrator shall have the power to award any remedies available under applicable law, and the
arbitrator shall award attorneys’ fees and costs to the prevailing party, except as prohibited by law. The Company will pay for any administrative or hearing fees charged by the administrator or JAMS, except that Executive shall pay any filing
fees associated with any arbitration that Executive initiates, but only so much of the filing fee as Executive would have instead paid had Executive filed a complaint in a court of law. Executive agrees that the arbitrator shall administer and
conduct any arbitration in accordance with California law, including the California Code of Civil Procedure, and that the arbitrator shall apply substantive and procedural California law to any dispute or claim, without reference to the rules of
conflict of law. To the extent that the JAMS Rules conflict with California law, California law shall take precedence. The decision of the arbitrator shall be in writing. Any arbitration under this Agreement shall be conducted in Santa Clara County,
California. 

  
 7 

 (d) Remedy. Except as provided by the Act, arbitration shall be the sole, exclusive, and
final remedy for any dispute between Executive and the Company. Accordingly, except as provided by the Act and this Agreement, neither Executive nor the Company will be permitted to pursue court action regarding claims that are subject to
arbitration. Notwithstanding, the arbitrator will not have the authority to disregard or refuse to enforce any lawful Company policy, and the arbitrator will not order or require the Company to adopt a policy not otherwise required by law which the
Company has not adopted. 
 (e) Administrative Relief. Executive is not prohibited from pursuing an administrative claim with a
local, state, or federal administrative body or government agency that is authorized to enforce or administer laws related to employment, including, but not limited to, the Department of Fair Employment and Housing, the Equal Employment Opportunity
Commission, the National Labor Relations Board, or the Workers’ Compensation Board. However, Executive may not pursue court action regarding any such claim, except as permitted by law. 

(f) Voluntary Nature of Agreement. Executive acknowledges and agrees that Executive is executing this Agreement voluntarily and without
any duress or undue influence by the Company or anyone else. Executive further acknowledges and agrees that Executive has carefully read this Agreement and that Executive has asked any questions needed for Executive to understand the terms,
consequences and binding effect of this Agreement and fully understands it, including that EXECUTIVE IS WAIVING EXECUTIVE’S RIGHT TO A JURY TRIAL. Finally, Executive agrees that Executive has been provided an opportunity to seek the
advice of an attorney of Executive’s choice before signing this Agreement. 
 14. Indemnification. The Company shall enter into
an indemnification agreement with Executive in form and substance similar to the indemnification agreement to be entered into between the Company and each of the members of its Board of Directors. 

15. Miscellaneous Provisions. 

(a) No Duty to Mitigate. Executive will not be required to mitigate the amount of any payment contemplated by this Agreement, nor will
any such payment be reduced by any earnings that Executive may receive from any other source. 
 (b) Amendment. No provision of this
Agreement will be modified, waived or discharged unless the modification, waiver or discharge is agreed to in writing and signed by Executive and by an authorized officer of the Company (other than Executive) that is expressly designated as an
amendment to this Agreement. 
 (c) Integration. This Agreement, together with the RSPA, and the Confidential Information Agreement
represents the entire agreement and understanding between the parties as to the subject matter herein and supersedes all prior or contemporaneous agreements whether written or oral. This Agreement may be modified only by agreement of the parties by
a written instrument executed by the parties that is designated as an amendment to this Agreement. 
 (d) Waiver of Breach. The
waiver of a breach of any term or provision of this Agreement, which must be in writing, will not operate as or be construed to be a waiver of any other previous or subsequent breach of this Agreement. 

(e) Headings. All captions and section headings used in this Agreement are for convenient reference only and do not form a part of this
Agreement. 

  
 8 

 (f) Tax Withholding. All payments made pursuant to this Agreement will be subject to all
applicable withholdings, including all applicable income and employment taxes, as determined in the Company’s reasonable judgment. 

(g) Governing Law. This Agreement will be governed by the laws of the State of California (with the exception of its conflict of laws
provisions). 
 (h) Severability. The invalidity or unenforceability of any provision or provisions of this Agreement will not affect
the validity or enforceability of any other provision hereof, which will remain in full force and effect. 
 16. Acknowledgment.
Executive acknowledges that he has had the opportunity to discuss this matter with and obtain advice from Executive’s private attorney, has had sufficient time to, and has carefully read and fully understands all the provisions of this
Agreement, and is knowingly and voluntarily entering into this Agreement. 
 17. Counterparts. This Agreement may be executed in
counterparts, and each counterpart will have the same force and effect as an original and will constitute an effective, binding agreement on the part of each of the undersigned. 

[Signature Page Follows] 

  
 9 

 IN WITNESS WHEREOF, each of the parties has executed this Agreement, in the case of the Company
by their duly authorized officers, as of the day and year first above written. 
  

									
	COMPANY:	  		  		  	
				
	CALITHERA BIOSCIENCES INC.	  		  		  	
					
	By:	  	 /s/ Ralph Christoffersen
	  		  	Date:	  	 June 17, 2010

	Title:	  	 Chairman, Board of Directors
	  		  		  	
				
	EXECUTIVE:	  		  		  	
				
	 /s/ Susan Molineaux
	  		  	Date:	  	 June 17, 2010

	Susan Molineaux	  		  		  	

 [SIGNATURE PAGE TO SUSAN MOLINEAUX EMPLOYMENT AGREEMENT] 

 EXHIBIT A 

FORM OF RELEASE AGREEMENT 

I understand that my position with Calithera Biosciences Inc. (the “Company”) terminated effective
                    ,          (the “Separation Date”). The Company has agreed that
if I choose to sign this Release, the Company will extend to me certain benefits (minus the standard withholdings and deductions, if applicable) pursuant to the terms of my Employment Agreement with the Company (the
“Agreement”) effective as of June 1, 2010. I understand that I am not entitled to such severance benefits unless I sign this Release. I understand that, regardless of whether I sign this Release, the Company will pay me
all of my accrued salary and vacation through the Separation Date, to which I am entitled by law. 
 In consideration for the severance
benefits I am receiving under the Agreement, I hereby release the Company and its officers, directors, agents, attorneys, employees, shareholders, parents, subsidiaries, and affiliates from any and all claims, liabilities, demands, causes of action,
attorneys’ fees, damages, or obligations of every kind and nature, whether they are now known or unknown, arising at any time prior to the date I sign this Release. This general release includes, but is not limited to: all federal and state
statutory and common law claims, claims related to my employment or the termination of my employment or related to breach of contract, tort, wrongful termination, discrimination, wages or benefits, or claims for any form of equity or compensation.
Notwithstanding the release in the preceding sentence, I am not releasing any (i) right of indemnification I may have for any liabilities arising from my actions within the course and scope of my employment with the Company or within the course
and scope of my role as a member of the Board of Directors of the Company, (ii) right to benefits under an employee benefit plan of the Company, (iii) right under the Agreement, and (iv) right under my Restricted Stock Purchase
Agreement with the Company dated March 24, 2010, and any stock option agreement or other equity award. 
 In releasing claims unknown
to me at present, I am waiving all rights and benefits under Section 1542 of the California Civil Code, and any law or legal principle of similar effect in any jurisdiction: “A general release does not extend to claims which the creditor
does not know or suspect to exist in his favor at the time of executing the release, which if known by him must have materially affected his settlement with the debtor.” 

If I am forty (40) years of age or older as of the Separation Date, I acknowledge that I am knowingly and voluntarily waiving and
releasing any rights I may have under the federal Age Discrimination in Employment Act of 1967, as amended (“ADEA”). I also acknowledge that the consideration given for the waiver in the above paragraph is in addition to
anything of value to which I was already entitled. I have been advised by this writing, as required by the ADEA that: (a) my waiver and release do not apply to any claims that may arise after my signing of this Release; (b) I should
consult with an attorney prior to executing this Release; (c) I have twenty-one (21) days within which to consider this Release (although I may choose to voluntarily execute this Release earlier); (d) I have seven (7) days
following the execution of this release to revoke the Release; and (e) this Release will not be effective until the eighth day after this Release has been signed both by me and by the Company (“Effective Date”). 

[Signature Page Follows] 

					
	Agreed:	 		 	
			
	  
	 		 	  

	Date	 		 	SUSAN MOLINEAUX

  
 12 

 CALITHERA BIOSCIENCES, INC. 

AMENDMENT NO. 1 TO THE SUSAN MOLINEAUX
EMPLOYMENT AGREEMENT 
 This AMENDMENT NO. 1 TO
THE SUSAN MOLINEAUX EMPLOYMENT AGREEMENT (the “Amendment”) is hereby entered into by and between Susan Molineaux (the
“Executive”) and Calithera Biosciences, Inc. (the “Company”) (together, the “Parties”) effective as of November 7, 2011 (the “Effective Date”), for
the purpose, as set forth below, to amend that certain Employment Agreement between the Parties dated June 17, 2010 (the “Employment Agreement”). All capitalized terms used and not defined herein shall have the meaning
as set forth in the Employment Agreement. 
 WHEREAS, the Company anticipates completing an equity
financing by means of the sale and issuance of its Series B Preferred Stock pursuant to that certain Series B Preferred Stock Purchase Agreement, dated November 7, 2011 (the “Closing”) for total aggregate proceeds to the
Company of approximately $4,000,000 (the “Financing”); and 
 WHEREAS, a
condition to the closing of the Financing, the Parties desire to amend the Employment Agreement to provide the Executive with the severance benefits as contained herein; 

NOW, THEREFORE, in consideration of the mutual promises and
covenants contained herein, it is hereby agreed by and between the Parties as follows: 
 AGREEMENT 

1. The Parties agree as of the Effective Date until the closing of the Company’s next bona fide equity or debt financing to occur
after the date of the Financing (the “Subsequent Financing”), the Employment Agreement is hereby amended as follows: 

1.1 The first sentence of Section 7(a)(i) shall be amended as follows: 

“Severance Payment. Executive will receive severance pay in an amount equal, in the aggregate, to the sum of (x) six months
of Executive’s Base Salary (as in effect immediately prior to Executive’s termination) plus (y) a pro rated portion of Executive’s target Management Bonus for the year in which Executive’s employment is terminated,
calculated based on the Company’s proportional accomplishment of that year’s goals through the date of Executive’s termination (the “Prorated Bonus”) less applicable withholdings, to be paid as set forth in Section 7(c)
below.” 
 1.2 The first sentence of Section 7(c) shall be amended as follows: 

“Timing of Severance Payments. The Company will pay the severance amount payable to Executive under Section 7(a)(i) over the
six (6) month period immediately following Executive’s termination, in substantially equal installments, on the Company’s regular payroll schedule; provided, however, that no severance amounts or benefits will be paid or provided
until the separation agreement and release of claims described in Section 7(b) becomes effective or prior to the 60th day after Executive’s termination.” 

 2. Miscellaneous Provisions. 

2.1 Original Agreement. Except as expressly amended by this Amendment, the Employment Agreement shall remain in full force and effect.

 2.2 Termination. This Amendment shall automatically terminate and be of no further force and effect upon the closing of a
Subsequent Financing. Any such termination shall occur automatically without any further action on the part of the Parities hereto. Upon any such termination, the Employment Agreement, as in effect absent this Amendment, shall constitute the full
and complete understanding between the Parties with respect the subject matter thereto. 
 2.3 Whole Agreement. No agreements,
representations or understandings (whether oral or written and whether express or implied) which are not expressly set forth in the Employment Agreement, as amended by this Amendment, have been made or entered into by either party with respect to
the subject matter of this Amendment. 
 2.4 Counterparts. This Amendment may be executed in separate counterparts, any one of which
need not contain signatures of more than one party, but all of which taken together will constitute one and the same Amendment. 
 2.5
Choice of Law. All questions concerning the construction, validity and interpretation of this Amendment will be governed by the internal laws of the State of California. 

[SIGNATURE PAGE TO FOLLOW] 

 IN WITNESS WHEREOF, each of the Parties has executed this Amendment, in the case of the Company
by its duly authorized representative, effective as of the Effective Date. 
  

			
	Calithera BioSciences, Inc.
		
	By:	 	 /s/ Ralph Christoffersen

		 	Ralph Christoffersen
		
	Date:	 	11-7-2011

  

			
	Understood and Agreed:
	
	Executive
		
	By:	 	 /s/ Susan Molineaux

		 	Susan Molineaux
		
	Date:	 	11-7-2011

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}]]